Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC

• Published in: JTO clinical and research reports Vol. 4; no. 12; p. 100604
• Main Authors: Pedraz-Valdunciel, Carlos, Ito, Masaoki, Giannoukakos, Stavros, Giménez-Capitán, Ana, Molina-Vila, Miguel Ángel, Rosell, Rafael
• Format: Journal Article
• Language: English
• Published: United States Elsevier 01.12.2023
• Subjects: Biomarker; CircRUNX1; EGFR mutation; NSCLC; EGFR mutation; CircRUNX1; Biomarker; NSCLC

As recently evidenced by the ADAURA trial, most patients with stages IB to IIIA of resected EGFR-mutant lung adenocarcinoma benefit from osimertinib as adjuvant therapy. Nevertheless, predictive markers of response and recurrence are still an unmet need for more than 10% of these patients. Some circ...